Clinical Trial Search

Primary: Number of Participants With Stomatitis Grade ≥ 2 — 2; 83; 1 Participants — p=<0.001

Primary: Body Mass Index (BMI) — 34.9; 33.4; 34.4 kg/(meters squared) — p=0.11

Primary: Impact of the Patients' Arm Positioning on Clinical Evaluation of Bi-planar Spinal X-rays Using the EOS System - Spinal Sagittal Plane Parameters — 5.9; 7.6; 29.5; 33.55…

Primary: Area Under the Curve of Rosuvastatin From 0 to the Last Quantifiable Data Point (AUC0-tz) — 81.5; 87.8; 88.7; 126 nanomol (nmol) * hour (h) / Litre (L)

Primary: Upper Extremity - Pain Sensitivity to Various Experimentally Induced Pain Stimuli — 6; 14 Number of tests favoring arm/group

Primary: Change From Baseline in Volumetric Magnetic Resonance Imaging (vMRI) - Brain Boundary Shift Integral (BBSI) and Ventricular Boundary Shift Integral (VBSI) — 6.349…

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After End of Study Drug Treatment (SVR12) — 100; 100 Percentage of Participants

Primary: Retention — 85; 75 percentage of participants

Primary: Task Completion Time — 87; 343 seconds — p=<0.001

Primary: MADRS Rating Scale Change — 13.1; 15.2 units on a scale — p=0.17

Primary: Mean Change From Baseline in the Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog) — -2.0 units on a scale — p=<0.001

Primary: Maximum Observed Plasma Concentration of Hyoscine Butylbromide (Cmax) — 91; 80 picogram (pg)/millilitre (mL)

Primary: Progression Free Survival (Arm A) — 0.946; 0.892; 0.739; 0.685 proportion of patients with PFS

Primary: Proportion of Subjects With a Complete Response to Treatment — 72; 66; 11; 11 participants

Primary: Average Total Nasal Symptom Score (TNSS) During Environmental Exposure Chamber (EEC) Challenge Session at Week 24 — 3.83; 5.47; 7.45 Score on a Scale — p=<0.001